Abstract
This study aimed to estimate the budget impact of venetoclax incorporation for treatment of patients with acute myeloid leukemia (AML) (a rare disease) over 65 years of age or those with comorbidities contraindication for the use of intensive chemotherapy, from the perspective of the social security and the private healthcare sector in Argentina.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
